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OBJECTIVES: The EQ-5D is a multiattribute health
status measure that can be used to derive preferences-
based index scores for HRQL assessment. The objective
of the study was to elicit the Visual Analogue Scale (VAS)
and the Time Trade-off (TTO) scores of minor (indepen-
dent after stroke) and major (dependent after stroke)
stroke survivors, from social tariffs obtained from general
population samples. METHODS: A cross-sectional study
of 350 stroke survivors was conducted in Spain. They
were stratiﬁed as minor and major stoke, depending 
if they required help from another person for everyday
activities. The EQ-5D questionnaire was administered 
to stroke survivors. Responses to the questionnaire were
converted in single scores along a continuum extending
from death (0.0) to full health (1.0). RESULTS: The VAS
and the TTO scores varied considerably across minor and
major stroke survivors. The minor and major stroke sur-
vivor, mean VAS scores were 0.71 (0.23) and 0.33 (0.27)
respectively and mean for TTO scores were 0.73 (0.28)
and 0.21 (0.43) respectively. Minor and major stroke 
survivors were a signiﬁcant predictor of VAS and TTO
scores. CONCLUSIONS: Minor and major stroke sur-
vivors had a substantial inﬂuence on VAS and TTO
scores, as measured by the EQ-5D. Patients with major
stroke had much lower scores. Our data support the
EuroQol as a useful measure of health status after stroke.
Its simplicity is a deﬁnite advantage, because many stroke
survivors ﬁnd more complex instruments difﬁcult to com-
plete without help.
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OBJECTIVE: To project the impact of Ezetimibe 10mg
(EZ10) co-administration for typical CHD patient not
attaining TC goal with simvastatin 10mg (S10)
monotherapy in Finland on remaining life expectancy,
mean TC reduction, and percent reaching goal.
METHOD: A decision-analytic model is used to project
beneﬁts of lipid therapy. Clinical trial data on the distri-
bution of TC changes was used to project the percent of
patients reaching TC goal with ezetimibe co-administered
with current statin therapy compared to titration (up 
to the maximum approved dose of Simvastatin 80mg) to
attain goal TC. Impact of TC changes on life expectancy
was projected using Framingham risk equations and non-
coronary mortality rates from Statistics Finland. In the
base case the model was run for a 55 year old male on
treatment with S10 and having TC = 6mmol/L, and HDL
= 1.1mmol/L. The beneﬁts were also obtained for men
and women aged 35 to 75 years with TC 5.5 to 
8.0mmol/L. RESULTS: For a 55-year-old male CHD
patient with TC = 6mmol/L while on S10, Ezetimibe co-
administration with simvastatin is projected to increase
the remaining life expectancy from 10.8 to 11.24 years
compared to statin titration where 42% not at goal are
titrated at each dose (titration strategy I) and from 11.09
to 11.24 years compared to statin titration where all
patients not at goal were titrated to attain goal (titration
strategy II). Projected additional patients at TC goal per
100 treated and mean TC reduction are 10 and 3.66%
for titration strategy I, 57 and 14.5% for titration strat-
egy II, and 65 and 18.28% for EZ10 co-administration
with S10. CONCLUSION: For the patient proﬁle studied
EZ10 co-administration with current statin is projected
to bring more patients to goal and may increase survival
time compared to titrating statin.
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OBJECTIVE: Most of Health Related Quality of Life
(HRQL) questionnaires were developed in English lan-
guage countries and their use is extended to other coun-
tries after adaptation. However, with few exceptions,
little is known about scores equivalence across countries.
Minnesota Living with Heart Failure Questionnaire
(MLHFQ) is a widely used speciﬁc HRQL instrument 
for patients suffering from heart failure. For this disorder,
the New York Heart Association classiﬁcation (NYHA)
is the usual severity indicator. The aim of this study 
was to assess the MLHFQ scores for each NYHA class
and equivalence across countries. METHODS: Data
came from 13 countries (2780 individuals). A general
lineal model (adjusted by age and gender) was con-
structed to conﬁrm whether or not MLHFQ scores 
and NYHA class were consistent across countries (USA
as reference). Interaction between these variables was
included. To check differences between countries also
Bonferroni pair wise multiple contrast was applied.
